AKTX Akari Therapeutics, Plc
Latest News

$3.76-0.08 (-2.08%)3:25 PM 10/04/23

NASDAQ | $USD | Delayed

News

Show Full Stories

This feature available only for pro users

Type:

Date Range:

Akari Therapeutics GAAP EPS of $0.00

Akari Therapeutics announces existing investors support the company through $2M private placement financing

Akari Therapeutics regains compliance with Nasdaq minimum bid price requirement

Akari Therapeutics announces ADS ratio change

Akari Therapeutics GAAP EPS of $0.00

Akari Therapeutics stock dips on launch of $4M ADSs offering

Akari Therapeutics receives Nasdaq notice on minimum bid price rule

Akari Therapeutics GAAP EPS of $0.00

Akari Therapeutics announces $12.75M registered direct offering

Akari hits over five-month high on reprioritization of pipeline

Akari Therapeutics announces positive results from pre-clinical studies of eye disease treatment

Akari Therapeutics GAAP EPS of $0.00

Patient completes course with Akari's stem cell transplant related complication treatment

Akari Therapeutics appoints Melissa Bradford-Klug as COO

Akari Therapeutics net loss of $17.4M

Akari Therapeutics slips on $9M equity offering

Akari Therapeutics picks new CEO

Akari advances program for inhaled delivery of nomacopan for lung diseases

Akari says FDA agrees to use of new manufacturing process for nomacopan for trials

Akari Therapeutics to raise $6M in ADSs offering

Akari Therapeutics reports Q3 results

Akari nomacopan eyedrops reduced inflammation more than standard of care in model

Akari Therapeutics reports Q2 results

Akari Therapeutics announces private placement

Akari Therapeutics reports Q1 results

Akari shares rise after FDA 'fast track' status for skin disease treatment nomacopan

Akari Therapeutics reports FY results

Akari shares rise on Bullous Pemphigoid nomacopan late-stage study initiation

Akari Therapeutics inks nomacopan deal with U.S. Army in trauma

Akari Therapeutics reports Q3 results

Akari Therapeutics updates trial progress; returns to profitability

Akari Therapeutics' lead candidate shows encouraging preclinical action against inflammatory eye disease

Akari Therapeutics furthers clinal trials for Covid-19 pneumonia

Akari's nomacopan to enter late-stage skin blistering disorder study during next year

Akari Therapeutics reports Q2 results

Akari Therapeutics +7% on developmental plans of nomacopan for COVID-19

Akari Therapeutics to initiate late-stage nomacopan study in rare skin disorder

Akari Therapeutics receives $30M capital commitment

Akari Therapeutics reports Q1 results

Apellis on go to file U.S. application for pegcetacoplan for rare blood disorder

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.